Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement-Reference-Cited by-同舟云学术

Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement

Published:2022-03-14 Issue:4 Volume:40 Page:518-527
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Zinzani Pier Luigi¹^ORCID,Martelli Maurizio²,Ferrero S.³^ORCID,Gentile Massimo⁴,Laurenti Luca⁵^ORCID,Romana Mauro Francesca²,Sportoletti Paolo⁶^ORCID,Tedeschi Alessandra⁷^ORCID,Varettoni M.⁸^ORCID,Visco Carlo⁹^ORCID

Affiliation:

1. IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Università Degli Studi Bologna Italy

2. Hematology, Department of Translational and Precision Medicine ‘Sapienza’ University Rome Italy

3. Department of Molecular Biotechnologies and Health Sciences Division of Haematology University of Torino Torino Italy/AOU “Città Della Salute e Della Scienza di Torino” Torino Italy

4. UOC Ematologia AO Cosenza Cosenza Italy

5. Hematology Università Cattolica Del Sacro Cuore Policlinico A. Gemelli Rome Italy

6. Department of Medicine, Institute of Hematology‐Centro di Ricerche Emato‐Oncologiche (CREO) University of Perugia Perugia Italy

7. Hematology, Niguarda Cancer Center ASST Grande Ospedale Metropolitano Niguarda Milan Italy

8. Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy

9. Department of Medicine, Section of Hematology University of Verona Verona Italy

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2983

Reference36 articles.

1. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

2. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

3. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies

4. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

5. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression;Scientific Reports;2024-03-19

2. Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study;Hematology Reports;2024-01-18

3. Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario;Hematological Oncology;2024-01

4. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study;eClinicalMedicine;2023-08